Corvus Pharmaceuticals Statistics
Total Valuation
CRVS has a market cap or net worth of $1.19 billion. The enterprise value is $976.65 million.
| Market Cap | 1.19B |
| Enterprise Value | 976.65M |
Important Dates
The last earnings date was Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CRVS has 84.12 million shares outstanding. The number of shares has increased by 22.16% in one year.
| Current Share Class | 84.12M |
| Shares Outstanding | 84.12M |
| Shares Change (YoY) | +22.16% |
| Shares Change (QoQ) | +2.63% |
| Owned by Insiders (%) | 3.54% |
| Owned by Institutions (%) | 76.35% |
| Float | 72.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.29 |
| P/TBV Ratio | 5.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.16, with a Debt / Equity ratio of 0.00.
| Current Ratio | 16.16 |
| Quick Ratio | 15.88 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -35.43% and return on invested capital (ROIC) is -23.17%.
| Return on Equity (ROE) | -35.43% |
| Return on Assets (ROA) | -21.66% |
| Return on Invested Capital (ROIC) | -23.17% |
| Return on Capital Employed (ROCE) | -25.25% |
| Weighted Average Cost of Capital (WACC) | 9.03% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.46M |
| Employee Count | 37 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +157.46% in the last 52 weeks. The beta is 0.87, so CRVS's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | +157.46% |
| 50-Day Moving Average | 14.25 |
| 200-Day Moving Average | 13.65 |
| Relative Strength Index (RSI) | 47.77 |
| Average Volume (20 Days) | 742,792 |
Short Selling Information
The latest short interest is 19.13 million, so 22.74% of the outstanding shares have been sold short.
| Short Interest | 19.13M |
| Short Previous Month | 18.31M |
| Short % of Shares Out | 22.74% |
| Short % of Float | 26.28% |
| Short Ratio (days to cover) | 22.00 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -56.96M |
| Pretax Income | -54.13M |
| Net Income | -54.13M |
| EBITDA | -56.85M |
| EBIT | -56.96M |
| Earnings Per Share (EPS) | -$0.62 |
Balance Sheet
The company has $215.23 million in cash and $728,000 in debt, with a net cash position of $214.50 million or $2.55 per share.
| Cash & Cash Equivalents | 215.23M |
| Total Debt | 728,000 |
| Net Cash | 214.50M |
| Net Cash Per Share | $2.55 |
| Equity (Book Value) | 225.33M |
| Book Value Per Share | 2.68 |
| Working Capital | 207.29M |
Cash Flow
In the last 12 months, operating cash flow was -$44.53 million and capital expenditures -$698,000, giving a free cash flow of -$45.23 million.
| Operating Cash Flow | -44.53M |
| Capital Expenditures | -698,000 |
| Depreciation & Amortization | 117,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -45.23M |
| FCF Per Share | -$0.54 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CRVS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.16% |
| Shareholder Yield | n/a |
| Earnings Yield | -4.54% |
| FCF Yield | -3.80% |
Analyst Forecast
The average price target for CRVS is $33.14, which is 134.04% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $33.14 |
| Price Target Difference | 134.04% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |